MK-0626

MK-0626 is a selective, orally active DPP-4 inhibitor with an IC50 of 6.3 nM. MK-0626 increases endothelial nitric oxide synthetase expression. MK-0626 improves neovascularization, attenuates hepatic steatosis, attenuates pancreatic islet injury. MK-0626 can be used in the research of diabetes and non-alcoholic fatty liver disease[1][2][3].

Product Specifications

CAS Number

[690257-74-0]

UNSPSC

12352005

Target

Dipeptidyl Peptidase; NO Synthase

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Field of Research

Cardiovascular Disease; Metabolic Disease

Smiles

O=C(N1CC(F)(CC1)F)[C@@H](N)[C@H](C2=CC=C(C3=CN4C(C=C3)=NC=N4)C=C2)C(N(C)C)=O

Molecular Formula

C22H24F2N6O2

Molecular Weight

442.46

References & Citations

[1]Shih CM, et al. MK-0626, a dipeptidyl peptidase-4 inhibitor, improves neovascularization by increasing both the number of circulating endothelial progenitor cells and endothelial nitric oxide synthetase expression. Curr Med Chem. 2014 Jun;21 (17) :2012-22. |[2]Ohyama T, et al. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice. World J Gastroenterol. 2014 Nov 21;20 (43) :16227-35. |[3]Jin L, et al. Dipeptidyl peptidase IV inhibitor MK-0626 attenuates pancreatic islet injury in tacrolimus-induced diabetic rats. PLoS One. 2014 Jun 24;9 (6) :e100798.